Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population
Open Access
- 20 October 2014
- journal article
- clinical trial
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10), e110691
- https://doi.org/10.1371/journal.pone.0110691
Abstract
The CYP2D6 enzyme is one of the most important members of the cytochrome P450 superfamily. This enzyme metabolizes approximately 25% of currently prescribed medications. The CYP2D6 gene presents a high allele heterogeneity that determines great inter-individual variation. The aim of this study was to evaluate the variability of CYP2D6 alleles, genotypes and predicted phenotypes in Brazilians. Eleven single nucleotide polymorphisms and CYP2D6 duplications/multiplications were genotyped by TaqMan assays in 1020 individuals from North, Northeast, South, and Southeast Brazil. Eighteen CYP2D6 alleles were identified in the Brazilian population. The CYP2D6*1 and CYP2D6*2 alleles were the most frequent and widely distributed in different geographical regions of Brazil. The highest number of CYPD6 alleles observed was six and the frequency of individuals with more than two copies ranged from 6.3% (in Southern Brazil) to 10.2% (Northern Brazil). The analysis of molecular variance showed that CYP2D6 is homogeneously distributed across different Brazilian regions and most of the differences can be attributed to inter-individual differences. The most frequent predicted metabolic status was EM (83.5%). Overall 2.5% and 3.7% of Brazilians were PMs and UMs respectively. Genomic ancestry proportions differ only in the prevalence of intermediate metabolizers. The IM predicted phenotype is associated with a higher proportion of African ancestry and a lower proportion of European ancestry in Brazilians. PM and UM classes did not vary among regions and/or ancestry proportions therefore unique CYP2D6 testing guidelines for Brazilians are possible and could potentially avoid ineffective or adverse events outcomes due to drug prescriptions.This publication has 53 references indexed in Scilit:
- Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs?Basic & Clinical Pharmacology & Toxicology, 2013
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic AntidepressantsClinical Pharmacology & Therapeutics, 2013
- CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCRPharmacogenomics, 2012
- Influence of Genomic Ancestry on the Distribution of SLCO1B1, SLCO1B3 and ABCB1 Gene Polymorphisms among BraziliansBasic & Clinical Pharmacology & Toxicology, 2011
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeClinical Pharmacology & Therapeutics, 2011
- The Genomic Ancestry of Individuals from Different Geographical Regions of Brazil Is More Uniform Than ExpectedPLOS ONE, 2011
- WINPEPI updated: computer programs for epidemiologists, and their teaching potentialEpidemiologic Perspectives & Innovations, 2011
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian populationBiomarkers, 2009